Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
DOI:
https://doi.org/10.12775/JEHS.2024.65.55504Keywords
alopecia areata, treatment, dermatology, autoimmune diseases, quality of lifeAbstract
Introduction and purpose: Alopecia Areata (AA) is an inflammatory autoimmune disorder characterized by non-scarring hair loss. While it is not life-threatening, it can lead to significant psychological distress. With advancements in modern medicine, new treatments, personalized therapies, and various therapeutic options have emerged. The aim of this study is to review and assess the efficacy, outcomes, and side effects of the available treatment options.
Material and methods : To compile this article “PUBMED” and “Google Scholar” databases were used with the great attention given to the articles not older than the year 2018
Brief description of the state of knowledge: There are various treatment options for Alopecia Areata (AA), beginning with topical treatments such as corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. In more severe cases, systemic therapy, biological therapy, or alternative treatments should be considered.
Results and conclusions: In the treatment of mild Alopecia Areata (AA), topical therapies are the preferred option due to their minimal side effects and easy to apply nature, with corticosteroids demonstrating the best outcomes, particularly when used in combination therapies. In patients with moderate or severe AA, systemic therapies are recommended, alone or in combination with topical treatment. In patients resistant to other forms of therapy, biological treatments or less commonly used methods should be considered.
References
Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017 Mar 16;3:17011. doi: 10.1038/nrdp.2017.11. PMID: 28300084; PMCID: PMC5573125.
Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022 Jun;86(6):1318-1334. doi: 10.1016/j.jaad.2021.04.077. Epub 2021 Apr 30. PMID: 33940103; PMCID: PMC8556406.
Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020 Aug;29(8):703-725. doi: 10.1111/exd.14155. PMID: 32682334.
Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022 Aug 30;13:955035. doi: 10.3389/fimmu.2022.955035. PMID: 36110853; PMCID: PMC9470217.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403. doi: 10.2147/CCID.S53985. PMID: 26244028; PMCID: PMC4521674.
Kalkan G, Seçkin HY, Benli İ, Akbaş A, Baş Y, Karakus N, Bütün İ, Özyurt H. Relationship between manganese superoxide dismutase (MnSODAla-9Val) and glutathione peroxidase (GPx1 Pro 197 Leu) gene polymorphisms and alopecia areata. Int J Clin Exp Med. 2015 Nov 15;8(11):21533-40. PMID: 26885102; PMCID: PMC4723947.
Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Böhm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PIW, Nöthen MM, Daly MJ, Christiano AM. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015 Jan 22;6:5966. doi: 10.1038/ncomms6966. PMID: 25608926; PMCID: PMC4451186.
Barahmani N, de Andrade M, Slusser JP, Wei Q, Hordinsky M, Price VH, Christiano A, Norris D, Reveille J, Duvic M. Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol. 2008 Jan;128(1):240-3. doi: 10.1038/sj.jid.5700973. Epub 2007 Jul 19. PMID: 17637820.
Rudnicka L, Rakowska A, Kerzeja M, Olszewska M. Hair shafts in trichoscopy: clues for diagnosis of hair and scalp diseases. Dermatol Clin. 2013 Oct;31(4):695-708, x. doi: 10.1016/j.det.2013.06.007. PMID: 24075554.
Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006 Nov;55(5):799-806. doi: 10.1016/j.jaad.2006.04.058. Epub 2006 Jul 28. PMID: 17052485.
Rakowska A, Rudnicka L, Olszewska M, Bergler-Czop B, Czuwara J, Brzezińska-Wcisło L et al. Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment. Dermatology Review/Przegląd Dermatologiczny. 2023;110(2):89-100. doi:10.5114/dr.2023.127704.
King BA, Senna MM, Ohyama M, Tosti A, Sinclair RD, Ball S, Ko JM, Glashofer M, Pirmez R, Shapiro J. Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework. Dermatol Ther (Heidelb). 2022 Apr;12(4):825-834. doi: 10.1007/s13555-022-00711-3. Epub 2022 Mar 31. PMID: 35357658; PMCID: PMC9021348.
Rakowska A, Rudnicka L, Olszewska M, Bergler-Czop B, Czuwara J, Brzezińska-Wcisło L et al. Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment. Dermatology Review/Przegląd Dermatologiczny. 2023;110(2):101-120. doi:10.5114/dr.2023.127705.
Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021 May;21(2):215-230. doi: 10.1007/s10238-020-00673-w. Epub 2021 Jan 1. PMID: 33386567.
Majid I, Keen A. Management of alopecia areata: an update. Br J Med Pract. 2012;5(3)
Chantal Bolduc M. Alopecia areata treatment & management [Internet]. Medscape; 2024 [cited 2024 Sept 18]. Available from: https://emedicine.medscape.com/article/1069931-treatment#d12?form=fpf
Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia Areata: Current Treatments and New Directions. Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22. PMID: 37606849.
Alkhalifah A. Topical and intralesional therapies for alopecia areata. Dermatol Ther. 2011 May-Jun;24(3):355-63. doi: 10.1111/j.1529-8019.2011.01419.x. PMID: 21689245.
Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107-15. doi: 10.2147/CCID.S22767. Epub 2011 Jul 22. PMID: 21833161; PMCID: PMC3149478.
Nomiyama T, Katoh N. Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure. Australas J Dermatol. 2021 May;62(2):e262-e264. doi: 10.1111/ajd.13479. Epub 2021 Jan 3. PMID: 33393075.
Lee YY, Lim HH, Son S, Jin S, Shin JM, Hong DK, Jung KE, Seo YJ, Lee TK, Kim YM, Lee Y. Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis. Clin Exp Dermatol. 2024 Mar 19:llae085. doi: 10.1093/ced/llae085. Epub ahead of print. PMID: 38501938.
Devi M, Rashid A, Ghafoor R. Intralesional Triamcinolone Acetonide Versus Topical Betamethasone Valearate in the Management of Localized Alopecia Areata. J Coll Physicians Surg Pak. 2015 Dec;25(12):860-2. PMID: 26691357.
Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol. 2009 Oct;8(10):909-12. PMID: 19852119.
Yee BE, Tong Y, Goldenberg A, Hata T. Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2020 Apr;82(4):1018-1021. doi: 10.1016/j.jaad.2019.11.066. Epub 2019 Dec 13. PMID: 31843657.
Suchonwanit P, Kositkuljorn C, Mahasaksiri T, Leerunyakul K. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J Dermatolog Treat. 2022 Mar;33(2):756-761. doi: 10.1080/09546634.2020.1773384. Epub 2020 Jun 9. PMID: 32441159.
Wolf R, Matz H, Zalish M, Pollack A, Orion E. Prostaglandin analogs for hair growth: great expectations. Dermatol Online J. 2003 Aug;9(3):7. PMID: 12952754.
Razi-Khosroshahi M, Sobhani S, Yousefi KM, Harooni G, Mashayekhi F, Balasi J, et al. Latanoprost in treatment of alopecia areata and androgenic alopecia: A comprehensive review. P J M H S. 2021;15(4):1535-1539.
Jiang S, Hao Z, Qi W, Wang Z, Zhou M, Guo N. The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis. Front Med (Lausanne). 2023 Mar 14;10:1130623. doi: 10.3389/fmed.2023.1130623. PMID: 36999072; PMCID: PMC10043424.
Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015 Apr;72(4):712-6. doi: 10.1016/j.jaad.2014.10.012. Epub 2015 Jan 16. PMID: 25601618.
Bhat S, Handa S, De D. A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):42-48. doi: 10.25259/IJDVL_787_19. PMID: 33580923.
Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-Label Use of Topical Minoxidil in Alopecia: A Review. Am J Clin Dermatol. 2019 Apr;20(2):237-250. doi: 10.1007/s40257-018-0409-y. PMID: 30604379.
Park H, Kim JE, Choi JW, Kim DY, Jang YH, Lee Y, Jeon J, Shin HT, Kim MS, Shin JW, Cho SB, Lew BL, Choi GS. Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment. Ann Dermatol. 2023 Jun;35(3):205-216. doi: 10.5021/ad.22.167. PMID: 37290954; PMCID: PMC10258553.
Georgala S, Befon A, Maniatopoulou E, Georgala C. Topical use of minoxidil in children and systemic side effects. Dermatology. 2007;214(1):101-2. doi: 10.1159/000096924. PMID: 17191059.
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. PMID: 24848508.
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019 Aug 9;13:2777-2786. doi: 10.2147/DDDT.S214907. Erratum in: Drug Des Devel Ther. 2020 Feb 10;14:575. doi: 10.2147/DDDT.S247601. PMID: 31496654; PMCID: PMC6691938.
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020 Jul;83(1):123-130. doi: 10.1016/j.jaad.2020.03.004. Epub 2020 Mar 9. PMID: 32165196.
Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichology. 2010 Jan;2(1):36-9. doi: 10.4103/0974-7753.66911. PMID: 21188022; PMCID: PMC3002409.
Sakai K, Fukushima S, Mizuhashi S, Jinnin M, Makino T, Inoue Y, Ihn H. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients. Allergol Int. 2020 Apr;69(2):274-278. doi: 10.1016/j.alit.2019.10.008. Epub 2019 Nov 22. PMID: 31767273.
Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001 Aug;137(8):1063-8. PMID: 11493099.
Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):751-61. doi: 10.1016/s0190-9622(98)70048-9. PMID: 9810892.
Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10. PMID: 25208745.
Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol. 2004 Jan;13(1):5-10. doi: 10.1111/j.0906-6705.2004.00098.x. PMID: 15009110.
Nelson DA, Spielvogel RL. Anthralin therapy for alopecia areata. Int J Dermatol. 1985 Nov;24(9):606-7. doi: 10.1111/j.1365-4362.1985.tb05863.x. PMID: 3905640.
Shah RR, Nazar Z, Swearingen A, Waqas N, Sharif S, Rao B. Anthralin’s applicability in the treatment of pediatric alopecia areata. J Clin Aesthet Dermatol. 2023;16(3 Suppl 1)–S33.
Zafrir Y, Tantuco K, Tangtatco AJA, Ho N. A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population. J Cutan Med Surg. 2023 Sep-Oct;27(5):449-453. doi: 10.1177/12034754231191060. Epub 2023 Aug 9. PMID: 37559401; PMCID: PMC10616981.
Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987 Nov;123(11):1491-3. PMID: 3314718.
Durdu M, Özcan D, Baba M, Seçkin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol. 2015 Apr;72(4):640-50. doi: 10.1016/j.jaad.2015.01.008. Epub 2015 Feb 1. PMID: 25653027.
Ibrahim SA, Esawy AM, Abdelshafy AS. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin. Dermatol Ther. 2019 Sep;32(5):e13010. doi: 10.1111/dth.13010. Epub 2019 Jul 8. PMID: 31237076.
Ghandi N, Daneshmand R, Hatami P, Abedini R, Nasimi M, Aryanian Z, Vance TM. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. Int Immunopharmacol. 2021 Oct;99:107971. doi: 10.1016/j.intimp.2021.107971. Epub 2021 Jul 20. PMID: 34298402.
Thuangtong R, Suvansuthi S, Maneeprasopchoke P, Sukakul T, Techakajornkeart R, Chaweekulrat P, Wongdama S, Triwongwaranat D. Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study. Int J Trichology. 2022 May-Jun;14(3):91-96. doi: 10.4103/ijt.ijt_72_21. Epub 2022 May 24. PMID: 35755959; PMCID: PMC9231531.
Behrangi E, Roohaninasab M, Sadeghzadeh-Bazargan A, Najar Nobari N, Ghassemi M, Seirafianpour F, Goodarzi A, Dodangeh M. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based on clinical studies. J Cosmet Dermatol. 2022 Jul;21(7):2727-2741. doi: 10.1111/jocd.14480. Epub 2021 Oct 4. PMID: 34606676.
Nasimi M, Ghandi N, Abedini R, Mirshamsi A, Shakoei S, Seirafi H. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Arch Dermatol Res. 2019 Oct;311(8):607-613. doi: 10.1007/s00403-019-01940-x. Epub 2019 Jun 5. PMID: 31165933.
Özdemir M, Balevi A. Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. Pediatr Dermatol. 2017 Mar;34(2):128-132. doi: 10.1111/pde.13049. Epub 2017 Jan 3. PMID: 28044367.
Rastaghi F, Kaveh R, Yazdanpanah N, Sahaf AS, Ahramyanpour N. The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata: A Review Article. Dermatol Pract Concept. 2023 Oct 1;13(4):e2023255. doi: 10.5826/dpc.1304a255. PMID: 37992355; PMCID: PMC10656135.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015 Jul 1;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2. PMID: 26132597; PMCID: PMC6461158.
Park SW, Kim JW, Wang HY. Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol. 2002;82(5):387-8. doi: 10.1080/000155502320624203. PMID: 12430746.
Bimbi C, Kyriakou G, Wollina U. Occlusive treatment enhances efficacy of tacrolimus 0.1% in a pediatric patient with severe alopecia areata: Case report and literature review. Pediatr Dermatol. 2021 Jan;38(1):339-340. doi: 10.1111/pde.14474. Epub 2020 Nov 27. PMID: 33247446.
Bimbi C, Kyriakou G, Wollina U. Occlusive treatment enhances efficacy of tacrolimus 0.1% in a pediatric patient with severe alopecia areata: Case report and literature review. Pediatr Dermatol. 2021 Jan;38(1):339-340. doi: 10.1111/pde.14474. Epub 2020 Nov 27. PMID: 33247446.
Hossain MS, Miah MT, Khan MZH, Khondker L, Hasan MR. Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. J Pak Assoc Dermatol [Internet]. 2016Nov.20 [cited 2024Sep.18];25(3):197-201. Available from: https://jpad.com.pk/index.php/jpad/article/view/109
Sotiriou E, Patsatsi A, Fotiadou C, Sotiriadis D, Panagiotidou D. Tacrolimus ointment 0.1% in the treatment of active patchy alopecia areata of childhood. Eur. J. Pediat. Dermatol. [Internet]. 2007Dec.31 [cited 2024Sep.18];17(4):227-30. Available from: https://ejpd.com/index.php/journal/article/view/409
Nassar A, Elradi M, Radwan M, Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study. J Cosmet Dermatol. 2023 Apr;22(4):1297-1303. doi: 10.1111/jocd.15558. Epub 2022 Dec 27. PMID: 36575890.
Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992 Nov;128(11):1467-73. PMID: 1444500.
Lobato-Berezo A, March-Rodríguez A, Grimalt R, Rodríguez-Lomba E, Setó-Torrent N, Pujol RM, Ruiz-Villaverde R. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: A multicentric study. Dermatol Ther. 2022 Nov;35(11):e15806. doi: 10.1111/dth.15806. Epub 2022 Sep 16. PMID: 36070222.
Alqarni AM, Zeidler MP. How does methotrexate work? Biochem Soc Trans. 2020 Apr 29;48(2):559-567. doi: 10.1042/BST20190803. PMID: 32239204.
Albela H, Begum S, Wee AL, Ponnuthurai N, Leong KF. Efficacy and Tolerability of Methotrexate in the Treatment of Severe Paediatric Alopecia Areata. Skin Appendage Disord. 2022 May;8(3):206-210. doi: 10.1159/000521238. Epub 2022 Jan 10. PMID: 35707294; PMCID: PMC9149515.
Lim SK, Lim CA, Kwon IS, Im M, Seo YJ, Kim CD, Lee JH, Lee Y. Low-Dose Systemic Methotrexate Therapy for Recalcitrant Alopecia Areata. Ann Dermatol. 2017 Jun;29(3):263-267. doi: 10.5021/ad.2017.29.3.263. Epub 2017 May 11. PMID: 28566900; PMCID: PMC5438930.
Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 Jan;80(1):120-127.e2. doi: 10.1016/j.jaad.2018.06.064. Epub 2018 Jul 10. PMID: 30003990.
Nowaczyk J, Makowska K, Rakowska A, Sikora M, Rudnicka L. Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review. Dermatol Ther (Heidelb). 2020 Jun;10(3):387-399. doi: 10.1007/s13555-020-00370-2. Epub 2020 Apr 8. PMID: 32270396; PMCID: PMC7211785.
Jang YH, Kim SL, Lee KC, Kim MJ, Park KH, Lee WJ, Lee SJ, Kim DW. A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata. Ann Dermatol. 2016 Oct;28(5):569-574. doi: 10.5021/ad.2016.28.5.569. Epub 2016 Sep 30. PMID: 27746635; PMCID: PMC5064185.
Saoji V, Kulkarni S, Madke B. Alopecia Areata Treated with Oral Azathioprine: A Case Series. Int J Trichology. 2019 Sep-Oct;11(5):219-222. doi: 10.4103/ijt.ijt_57_19. PMID: 31728106; PMCID: PMC6830026.
Raychaudhuri SP, Raychaudhuri SK. JAK inhibitor: Introduction. Indian J Dermatol Venereol Leprol. 2023 Sep-Oct;89(5):688-690. doi: 10.25259/IJDVL_8_2023. PMID: 37609754.
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17. PMID: 25129481; PMCID: PMC4362521.
Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020 Feb;82(2):412-419. doi: 10.1016/j.jaad.2019.10.016. Epub 2019 Oct 14. PMID: 31622643.
Liu LY, King BA. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents. J Investig Dermatol Symp Proc. 2018 Jan;19(1):S18-S20. doi: 10.1016/j.jisp.2017.10.003. PMID: 29273099.
Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024. PMID: 28619556.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.
Liu X, Song B, Jin H. Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up. J Asthma Allergy. 2024 Apr 2;17:305-311. doi: 10.2147/JAA.S458684. PMID: 38585501; PMCID: PMC10998503.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2024 Mar;25(2):299-314. doi: 10.1007/s40257-024-00846-3. Epub 2024 Jan 23. Erratum in: Am J Clin Dermatol. 2024 Jul;25(4):689. doi: 10.1007/s40257-024-00864-1. PMID: 38263353; PMCID: PMC10867086
Juhász MLW, Atanaskova Mesinkovska N. The use of phosphodiesterase inhibitors for the treatment of alopecia. J Dermatolog Treat. 2020 May;31(3):245-253. doi: 10.1080/09546634.2019.1592097. Epub 2019 Apr 2. PMID: 30935254.
Apremilast [Internet]. [cited 2024 Sept 19]. Available from: https://www.mp.pl/pacjent/leki/subst.html?id=5365
Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. 2015 Jan;77(1):74-6. doi: 10.1016/j.jdermsci.2014.11.009. Epub 2014 Dec 3. PMID: 25530115.
López SR, de Castro CG, Calzada PM, Segura PC. Alopecia areata and severe psoriasis successfully treated with Apremilast. [Internet]. SciTeMed Publishing Group; 2017 [cited 2024 Sept 18]. Available from: https://www.scitemed.com/article/207/scitemed-acd-2017-00033
ZHANG Fan, MI Zihao, SUN Yonghu. Topical phosphodiesterase-4 inhibitor in the treatment of alopecia areata: a case report and literature review[J].China Journal of Leprosy and Skin Diseases, 2022, 38(4): 217-219.
Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11. PMID: 30417279.
Estébanez A, Estébanez N, Martín JM, Montesinos E. Apremilast in Refractory Alopecia Areata. Int J Trichology. 2019 Sep-Oct;11(5):213-215. doi: 10.4103/ijt.ijt_59_19. PMID: 31728104; PMCID: PMC6830030
Olbrich H, Sadik CD, Ludwig RJ, Thaçi D, Boch K. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634. PMID: 37189381; PMCID: PMC10136243.
Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata. J Am Acad Dermatol. 2023 Mar;88(3):651-653. doi: 10.1016/j.jaad.2019.06.010. Epub 2019 Jun 13. PMID: 31391150.
Penzi LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM. Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab. JAMA Dermatol. 2018 Nov 1;154(11):1358-1360. doi: 10.1001/jamadermatol.2018.2976. PMID: 30304403.
Harada K, Irisawa R, Ito T, Uchiyama M, Tsuboi R. The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol. 2020 Aug;183(2):396-397. doi: 10.1111/bjd.18976. Epub 2020 Apr 8. PMID: 32118289.
Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022 Jan;49(1):19-36. doi: 10.1111/1346-8138.16207. Epub 2021 Oct 28. PMID: 34709679.
Gallo R, Trave I, Parodi A. Massive Acute Alopecia of the Scalp in a Patient Treated with Dupilumab. Acta Derm Venereol. 2020 Jun 18;100(13):adv00191. doi: 10.2340/00015555-3549. PMID: 32511738; PMCID: PMC9175043.
Kulkarni M, Rohan CA, Travers JB, Serrao R. Long-Term Efficacy of Dupilumab in Alopecia Areata. Am J Case Rep. 2022 Jun 21;23:e936488. doi: 10.12659/AJCR.936488. PMID: 35726185; PMCID: PMC9235915.
Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018 Sep;37(3):143-147. doi: 10.12788/j.sder.2018.040. PMID: 30215630.
Renert-Yuval Y, Guttman-Yassky E. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther. 2017 Jul;34(7):1594-1609. doi: 10.1007/s12325-017-0542-7. Epub 2017 Jun 23. PMID: 28646393; PMCID: PMC5504208.
Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, Khattri S, Min M, Mansouri Y, Zheng X, Estrada YD, Singer GK, Suarez-Farinas M, Krueger JG, Lebwohl MG. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016 Jan;137(1):301-304. doi: 10.1016/j.jaci.2015.11.001. Epub 2015 Nov 20. PMID: 26607705.
Aleisa A, Lim Y, Gordon S, Her MJ, Zancanaro P, Abudu M, Deverapalli SC, Madani A, Rosmarin D. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2019 Jan;36(1):e44-e45. doi: 10.1111/pde.13699. Epub 2018 Oct 18. PMID: 30338558.
Malhotra K, Madke B. An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options. Int J Trichology. 2023 Jan-Feb;15(1):3-12. doi: 10.4103/ijt.ijt_28_21. Epub 2023 Apr 19. PMID: 37305188; PMCID: PMC10251289.
Mackay-Wiggan J, Sallee BN, Wang EHC, Sansaricq F, Nguyen N, Kim C, Chen JC, Christiano AM, Clynes R. An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol. 2021 Mar;84(3):841-844. doi: 10.1016/j.jaad.2020.09.091. Epub 2020 Oct 9. PMID: 33045294.
Stępień M, Anczyk S. Cytokine-targeted treatment in alopecia areata - new possibilities?. Prosp. Pharm. Sc. [Internet]. 2023 May 8 [cited 2024 Sep. 18];21(2):22-9. Available from: https://prospects.wum.edu.pl/index.php/pps/article/view/133
Almohanna HM, Ahmed AA, Griggs JW, Tosti A. Platelet-Rich Plasma in the Treatment of Alopecia Areata: A Review. J Investig Dermatol Symp Proc. 2020 Nov;20(1):S45-S49. doi: 10.1016/j.jisp.2020.05.002. PMID: 33099384.
El Taieb MA, Ibrahim H, Nada EA, Seif Al-Din M. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. Dermatol Ther. 2017 Jan;30(1). doi: 10.1111/dth.12437. Epub 2016 Oct 28. PMID: 27791311.
Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfus. 2023 Jan;21(1):24-36. doi: 10.2450/2021.0216-21. Epub 2021 Nov 15. PMID: 34967722; PMCID: PMC9918380.
Welsh O. Phototherapy for alopecia areata. Clin Dermatol. 2016 Sep-Oct;34(5):628-32. doi: 10.1016/j.clindermatol.2016.05.014. Epub 2016 May 19. PMID: 27638443.
Sirichotiyakul P, Meephansan J, Suchonwanit P. UV308 excimer lamp phototherapy for the treatment of alopecia areata: A randomized, self-controlled study. Photodermatol Photoimmunol Photomed. 2020 Sep;36(5):405-407. doi: 10.1111/phpp.12570. Epub 2020 May 28. PMID: 32415885.
Herz-Ruelas ME, Welsh O, Gomez-Flores M, Welsh E, Miranda-Maldonado I, Ocampo-Candiani J. Ultraviolet A-1 phototherapy as an alternative for resistant alopecia areata. Int J Dermatol. 2015 Oct;54(10):e445-7. doi: 10.1111/ijd.13054. PMID: 26394604.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Julia Wójcik, Kacper Wojciech Pamuła, Marcin Cholewa, Wiktoria Maria Szymańska, Julia Plewniok, Maria Partyka, Karolina Jaglarz, Maciej Kuca, Maksymilian Janeczek, Adrian Uchto
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 78
Number of citations: 0